BioTech Weekly - Week 24 - Jun 9-15, 2025

🚀 Biotech & Life Sciences Weekly Highlights 🌱Privacy Under Fire: 27 states and D.C. are suing 23andMe to stop the sale of personal genetic data without consent — as Regeneron eyes acquisition during bankruptcy proceedings.Organoid Innovation: Pluristyx launches the PluriForm™ Organoid Kit, dramatically cutting down organoid development timelines with ready-to-differentiate iPSCs.Funding Milestone: Genesys Capital closes its largest fund yet — Genesys Ventures IV LP — backing Canadian life sciences with strong investor confidence.Rare Disease Breakthroughs: Chiesi Group partners with Key2Brain AB to advance blood-brain barrier-crossing therapies for lysosomal storage disorders.Next-Gen Neurotherapeutics: Enveric Biosciences secures a patent for low-hallucinogenic neuroplastogens, opening new doors in psychiatric treatment.🔍 Stay tuned — innovation is not slowing down!SourcesDozens of states sue to block the sale of 23andMe personal genetic data without customer consentPluristyx Launches PluriForm™ Organoid Kit, Slashing Weeks Off Organoid Development TimelinesGenesys Capital is Closing its Largest Fund to Date – Genesys Ventures IV LPChiesi Group Enters into Worldwide Licensing Agreement with Key2Brain ABEnveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic NeuroplastogensFive BIO 2025 events you don’t want to miss Layoff Tracker: Gilead Cuts 36 Employees in California 

There are no comments yet.

Please log in to write the first comment.